List of Tables
Table 1. Specific Antiviral Drugs for COVID-19 Market Trends
Table 2. Specific Antiviral Drugs for COVID-19 Market Drivers & Opportunity
Table 3. Specific Antiviral Drugs for COVID-19 Market Challenges
Table 4. Specific Antiviral Drugs for COVID-19 Market Restraints
Table 5. Global Specific Antiviral Drugs for COVID-19 Revenue by Company (2019-2024) & (US$ Million)
Table 6. Global Specific Antiviral Drugs for COVID-19 Revenue Market Share by Company (2019-2024)
Table 7. Key Companies Specific Antiviral Drugs for COVID-19 Manufacturing Base Distribution and Headquarters
Table 8. Key Companies Specific Antiviral Drugs for COVID-19 Product Type
Table 9. Key Companies Time to Begin Mass Production of Specific Antiviral Drugs for COVID-19
Table 10. Global Specific Antiviral Drugs for COVID-19 Companies Market Concentration Ratio (CR5 and HHI)
Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Specific Antiviral Drugs for COVID-19 as of 2023)
Table 12. Mergers & Acquisitions, Expansion Plans
Table 13. Global Specific Antiviral Drugs for COVID-19 Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
Table 14. Global Specific Antiviral Drugs for COVID-19 Sales Value by Type (2019-2024) & (US$ Million)
Table 15. Global Specific Antiviral Drugs for COVID-19 Sales Value by Type (2025-2030) & (US$ Million)
Table 16. Global Specific Antiviral Drugs for COVID-19 Sales Market Share in Value by Type (2019-2024) & (%)
Table 17. Global Specific Antiviral Drugs for COVID-19 Sales Market Share in Value by Type (2025-2030) & (%)
Table 18. Global Specific Antiviral Drugs for COVID-19 Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
Table 19. Global Specific Antiviral Drugs for COVID-19 Sales Value by Application (2019-2024) & (US$ Million)
Table 20. Global Specific Antiviral Drugs for COVID-19 Sales Value by Application (2025-2030) & (US$ Million)
Table 21. Global Specific Antiviral Drugs for COVID-19 Sales Market Share in Value by Application (2019-2024) & (%)
Table 22. Global Specific Antiviral Drugs for COVID-19 Sales Market Share in Value by Application (2025-2030) & (%)
Table 23. Global Specific Antiviral Drugs for COVID-19 Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
Table 24. Global Specific Antiviral Drugs for COVID-19 Sales Value by Region (2019-2024) & (US$ Million)
Table 25. Global Specific Antiviral Drugs for COVID-19 Sales Value by Region (2025-2030) & (US$ Million)
Table 26. Global Specific Antiviral Drugs for COVID-19 Sales Value by Region (2019-2024) & (%)
Table 27. Global Specific Antiviral Drugs for COVID-19 Sales Value by Region (2025-2030) & (%)
Table 28. Key Countries/Regions Specific Antiviral Drugs for COVID-19 Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
Table 29. Key Countries/Regions Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2024) & (US$ Million)
Table 30. Key Countries/Regions Specific Antiviral Drugs for COVID-19 Sales Value, (2025-2030) & (US$ Million)
Table 31. Sanofi Basic Information List
Table 32. Sanofi Description and Business Overview
Table 33. Sanofi Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 34. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sanofi (2019-2024)
Table 35. Sanofi Recent Developments
Table 36. Novartis Basic Information List
Table 37. Novartis Description and Business Overview
Table 38. Novartis Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 39. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Novartis (2019-2024)
Table 40. Novartis Recent Developments
Table 41. Shanghai Zhongxisanwei Basic Information List
Table 42. Shanghai Zhongxisanwei Description and Business Overview
Table 43. Shanghai Zhongxisanwei Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 44. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Shanghai Zhongxisanwei (2019-2024)
Table 45. Shanghai Zhongxisanwei Recent Developments
Table 46. Teva Basic Information List
Table 47. Teva Description and Business Overview
Table 48. Teva Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 49. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Teva (2019-2024)
Table 50. Teva Recent Developments
Table 51. Zydus Cadila Basic Information List
Table 52. Zydus Cadila Description and Business Overview
Table 53. Zydus Cadila Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 54. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Zydus Cadila (2019-2024)
Table 55. Zydus Cadila Recent Developments
Table 56. Mylan Basic Information List
Table 57. Mylan Description and Business Overview
Table 58. Mylan Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 59. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Mylan (2019-2024)
Table 60. Mylan Recent Developments
Table 61. Apotex Basic Information List
Table 62. Apotex Description and Business Overview
Table 63. Apotex Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 64. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Apotex (2019-2024)
Table 65. Apotex Recent Developments
Table 66. Advanz Pharma Basic Information List
Table 67. Advanz Pharma Description and Business Overview
Table 68. Advanz Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 69. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Advanz Pharma (2019-2024)
Table 70. Advanz Pharma Recent Developments
Table 71. Sun Pharma Basic Information List
Table 72. Sun Pharma Description and Business Overview
Table 73. Sun Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 74. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sun Pharma (2019-2024)
Table 75. Sun Pharma Recent Developments
Table 76. Kyung Poong Basic Information List
Table 77. Kyung Poong Description and Business Overview
Table 78. Kyung Poong Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 79. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Kyung Poong (2019-2024)
Table 80. Kyung Poong Recent Developments
Table 81. Ipca Laboratories Basic Information List
Table 82. Ipca Laboratories Description and Business Overview
Table 83. Ipca Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 84. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Ipca Laboratories (2019-2024)
Table 85. Ipca Laboratories Recent Developments
Table 86. Hanlim Pharmaceutical Basic Information List
Table 87. Hanlim Pharmaceutical Description and Business Overview
Table 88. Hanlim Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 89. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Hanlim Pharmaceutical (2019-2024)
Table 90. Hanlim Pharmaceutical Recent Developments
Table 91. Bristol Laboratories Basic Information List
Table 92. Bristol Laboratories Description and Business Overview
Table 93. Bristol Laboratories Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 94. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Bristol Laboratories (2019-2024)
Table 95. Bristol Laboratories Recent Developments
Table 96. Bayer Basic Information List
Table 97. Bayer Description and Business Overview
Table 98. Bayer Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 99. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Bayer (2019-2024)
Table 100. Bayer Recent Developments
Table 101. Rising Pharmaceutical Basic Information List
Table 102. Rising Pharmaceutical Description and Business Overview
Table 103. Rising Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 104. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Rising Pharmaceutical (2019-2024)
Table 105. Rising Pharmaceutical Recent Developments
Table 106. Shanghai Pharma Basic Information List
Table 107. Shanghai Pharma Description and Business Overview
Table 108. Shanghai Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 109. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Shanghai Pharma (2019-2024)
Table 110. Shanghai Pharma Recent Developments
Table 111. Sichuan Sunny Hope Basic Information List
Table 112. Sichuan Sunny Hope Description and Business Overview
Table 113. Sichuan Sunny Hope Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 114. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Sichuan Sunny Hope (2019-2024)
Table 115. Sichuan Sunny Hope Recent Developments
Table 116. Guangzhou Baiyunshan Guanghua Pharmaceutical Basic Information List
Table 117. Guangzhou Baiyunshan Guanghua Pharmaceutical Description and Business Overview
Table 118. Guangzhou Baiyunshan Guanghua Pharmaceutical Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 119. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Guangzhou Baiyunshan Guanghua Pharmaceutical (2019-2024)
Table 120. Guangzhou Baiyunshan Guanghua Pharmaceutical Recent Developments
Table 121. CSPC Group Basic Information List
Table 122. CSPC Group Description and Business Overview
Table 123. CSPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 124. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of CSPC Group (2019-2024)
Table 125. CSPC Group Recent Developments
Table 126. KPC Group Basic Information List
Table 127. KPC Group Description and Business Overview
Table 128. KPC Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 129. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of KPC Group (2019-2024)
Table 130. KPC Group Recent Developments
Table 131. Jinghua Pharmaceutical Group Basic Information List
Table 132. Jinghua Pharmaceutical Group Description and Business Overview
Table 133. Jinghua Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 134. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Jinghua Pharmaceutical Group (2019-2024)
Table 135. Jinghua Pharmaceutical Group Recent Developments
Table 136. Zhongsheng Pharma Basic Information List
Table 137. Zhongsheng Pharma Description and Business Overview
Table 138. Zhongsheng Pharma Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 139. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of Zhongsheng Pharma (2019-2024)
Table 140. Zhongsheng Pharma Recent Developments
Table 141. North China Pharmaceutical Group Basic Information List
Table 142. North China Pharmaceutical Group Description and Business Overview
Table 143. North China Pharmaceutical Group Specific Antiviral Drugs for COVID-19 Products, Services and Solutions
Table 144. Revenue (US$ Million) in Specific Antiviral Drugs for COVID-19 Business of North China Pharmaceutical Group (2019-2024)
Table 145. North China Pharmaceutical Group Recent Developments
Table 146. Key Raw Materials Lists
Table 147. Raw Materials Key Suppliers Lists
Table 148. Specific Antiviral Drugs for COVID-19 Downstream Customers
Table 149. Specific Antiviral Drugs for COVID-19 Distributors List
Table 150. Research Programs/Design for This Report
Table 151. Key Data Information from Secondary Sources
Table 152. Key Data Information from Primary Sources
Table 153. Business Unit and Senior & Team Lead Analysts
List of Figures
Figure 1. Specific Antiviral Drugs for COVID-19 Product Picture
Figure 2. Global Specific Antiviral Drugs for COVID-19 Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
Figure 3. Global Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 4. Specific Antiviral Drugs for COVID-19 Report Years Considered
Figure 5. Global Specific Antiviral Drugs for COVID-19 Players Revenue Ranking (2023) & (US$ Million)
Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Specific Antiviral Drugs for COVID-19 Revenue in 2023
Figure 7. Specific Antiviral Drugs for COVID-19 Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
Figure 8. Tablet Picture
Figure 9. Injection Picture
Figure 10. Global Specific Antiviral Drugs for COVID-19 Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
Figure 11. Global Specific Antiviral Drugs for COVID-19 Sales Value Market Share by Type, 2023 & 2030
Figure 12. Product Picture of Mild Symptom Patient
Figure 13. Product Picture of Critically Ill Patient
Figure 14. Global Specific Antiviral Drugs for COVID-19 Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
Figure 15. Global Specific Antiviral Drugs for COVID-19 Sales Value Market Share by Application, 2023 & 2030
Figure 16. North America Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 17. North America Specific Antiviral Drugs for COVID-19 Sales Value by Country (%), 2023 VS 2030
Figure 18. Europe Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 19. Europe Specific Antiviral Drugs for COVID-19 Sales Value by Country (%), 2023 VS 2030
Figure 20. Asia Pacific Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 21. Asia Pacific Specific Antiviral Drugs for COVID-19 Sales Value by Country (%), 2023 VS 2030
Figure 22. South America Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 23. South America Specific Antiviral Drugs for COVID-19 Sales Value by Country (%), 2023 VS 2030
Figure 24. Middle East & Africa Specific Antiviral Drugs for COVID-19 Sales Value (2019-2030) & (US$ Million)
Figure 25. Middle East & Africa Specific Antiviral Drugs for COVID-19 Sales Value by Country (%), 2023 VS 2030
Figure 26. Key Countries/Regions Specific Antiviral Drugs for COVID-19 Sales Value (%), (2019-2030)
Figure 27. United States Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 28. United States Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 29. United States Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 30. Europe Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 31. Europe Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 32. Europe Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 33. China Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 34. China Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 35. China Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 36. Japan Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 37. Japan Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 38. Japan Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 39. South Korea Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 40. South Korea Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 41. South Korea Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 42. Southeast Asia Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 43. Southeast Asia Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 44. Southeast Asia Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 45. India Specific Antiviral Drugs for COVID-19 Sales Value, (2019-2030) & (US$ Million)
Figure 46. India Specific Antiviral Drugs for COVID-19 Sales Value by Type (%), 2023 VS 2030
Figure 47. India Specific Antiviral Drugs for COVID-19 Sales Value by Application (%), 2023 VS 2030
Figure 48. Specific Antiviral Drugs for COVID-19 Industrial Chain
Figure 49. Specific Antiviral Drugs for COVID-19 Manufacturing Cost Structure
Figure 50. Channels of Distribution (Direct Sales, and Distribution)
Figure 51. Bottom-up and Top-down Approaches for This Report
Figure 52. Data Triangulation
